ABSTRACT BACKGROUND Patients with multiple sclerosis (MS) receiving disease-
modifying therapies (DMT) show published adherence rates of 27.0% to 93.8% and …

In this independent, multicenter, retrospective study, we investigated the short-term
persistence to treatment with first-line self-injectable or oral disease-modifying treatments …

Purpose To examine the long-term persistence to the first-line injectable disease-modifying
therapies (DMTs) for multiple sclerosis (MS) and to identify the factors associated with …

Background and purpose Treatment persistence is the continuation of therapy over time. It
reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world …

Background The availability of new disease-modifying treatments (DMTs) in the last years
has changed the therapeutic strategies used in Multiple Sclerosis (MS). We aimed to …

Objectives To analyse persistence and adherence in patients with multiple sclerosis
receiving first-line treatment with subcutaneous glatiramer acetate 20 mg (GA) …

Background Despite a recent interest in Real World Data, such studies are scarce in multiple
sclerosis (MS) disease. The objective was to describe the patients, disease progression and …

Purpose Treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Poland
begins with first-line therapy; however, the treatment often fails. The aim of this study was to …

(DMT) show published adherence rates of 27.0% to 93.8% and published persistence rates
of 49.7% to 96.5%. Improvements in DMT adherence and persistence are key to optimizing …

Background. Because of side effects, adherence to the treatment with β interferons in
multiple sclerosis (MS) is low, leading to decreased treatment efficacy. This can be …